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Aims/hypothesis: The metabolic syndrome
comprises a clustering of cardiovascular risk fac-
tors but the underlying mechanism is not known.
Mice with targeted disruption of endothelial nitric
oxide synthase (eNOS) are hypertensive and in-
sulin resistant. We wondered, whether eNOS
deficiency in mice is associated with a phenotype
mimicking the human metabolic syndrome. 
Methods and Results: In addition to arterial
pressure and insulin sensitivity (euglycaemic hy-
perinsulinaemic clamp), we measured the plasma
concentration of leptin, insulin, cholesterol,
triglycerides, free fatty acids, fibrinogen and uric
acid in 10 to 12 week old eNOS–/– and wild type
mice. We also assessed glucose tolerance under
basal conditions and following a metabolic stress
with a high fat diet. As expected eNOS–/– mice
were hypertensive and insulin resistant, as evi-
denced by fasting hyperinsulinaemia and a roughly
30 percent lower steady state glucose infusion rate
during the clamp. eNOS–/– mice had a 1.5 to 
2-fold elevation of the cholesterol, triglyceride and
free fatty acid plasma concentration. Even though
body weight was comparable, the leptin plasma
level was 30% higher in eNOS–/– than in wild type
mice. Finally, uric acid and fibrinogen were ele-
vated in the eNOS–/– mice. Whereas under basal
conditions, glucose tolerance was comparable in
knock out and control mice, on a high fat diet,
knock out mice became significantly more glucose
intolerant than control mice.
Conclusions: A single gene defect, eNOS defi-
ciency, causes a clustering of cardiovascular risk
factors in young mice. We speculate that defective
nitric oxide synthesis could trigger many of the
abnormalities making up the metabolic syndrome
in humans.
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Epidemiological studies demonstrate an asso-
ciation between insulin resistance, arterial hyper-
tension and cardiovascular morbidity [1]. The
hypertension-hyperglycaemia hyperuricaemia syn-
drome was first described by Kylin in 1923 [2].
Since then, dyslipidaemia, obesity, hyperleptin-
aemia and a hypercoagulable state have been 
added and the term metabolic syndrome was
coined to describe this clustering of cardiovascular
risk factors [3]. Moreover, subjects with the meta-
bolic syndrome are often insulin resistant. While
the exact underlying mechanism relating these dis-
orders is not known, there is evidence in humans
that a defect of nitric oxide synthesis could trigger
several of the metabolic and cardiovascular ab-
normalities characteristic of insulin-resistant sta-
tes [4]. Consistent with this hypothesis, prelimi-
nary evidence in mice with targeted disruption of
the endothelial nitric oxide synthase (eNOS) gene
suggests that in addition to being hypertensive,
these mice are also insulin resistant [5]. We won-
dered whether eNOS deficiency in mice was asso-
ciated with a phenotype resembling the metabolic
syndrome X in humans. In addition to arterial
pressure and insulin sensitivity (euglycaemic hy-
perinsulinaemic clamp), we therefore measured
leptin, insulin, cholesterol, triglycerides, free fatty
acid, uric acid and fibrinogen plasma concentra-
tion in eNOS–/– and wild type mice. We also as-
sessed glucose tolerance under basal conditions
and after a metabolic stress with a high-fat diet.
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Methods
All protocols were approved by the Institutional An-
imal Care and Use Committee. Homozygote eNOS–/–
female C57BL6 mice and wild type littermates generated
as previously described were studied [5]. Mice were
housed with light on from 7 a.m. to 7 p.m. and had free
access to water and normal chow diet (NC, UAR, Epinay
sur Orge, France, energy content: 12% fat, 28% protein
and 60% carbohydrate).
Measurement of arterial blood pressure
Arterial pressure was measured in conscious, partially
restrained, 10–12 week-old mice (n = 7 for each group)
using fluid filled PE-10 tubing connected to a pressure
transducer. The catheter was inserted under halothane
anaesthesia into the carotid artery and tunnelled subcuta-
neously to exit at the back of the neck 4 hours before the
measurement.
Euglycaemic hyperinsulinaemic clamp studies
Glucose turnover during the glucose clamp was
measured in freely moving mice after a 5 hour fast as
described previously [5]. Briefly, on the day of the clamp,
insulin (18 mU/kg per min) was infused into the femoral
vein for 3 hours. Euglycaemia was maintained by period-
ically adjusting a variable infusion of 16.5% glucose. The
glucose infusion rate was calculated as the mean of the
values obtained every 10 minutes during the last hour 
of the 3-hour infusion. Mice showing variations of these
parameters >15 percent were not included in the calcula-
tions. 9 eNOS–/– and 9 control mice were studied.
Intraperitoneal glucose tolerance test
Groups of at least 7 controls and eNOS–/– each were
fed either normal chow or carbohydrate free high fat diet
(HFD, UAR, Epinay sur Orge, France, energy content:
72% fat [corn oil and lard], 28% protein, and <1% carbo-
hydrate) for 6 weeks. On the day of the test, the mice were
fasted for five hours before intraperitoneal injection of
glucose (1 gram per kg body weight). Blood glucose con-
centration was measured with a glucometer (Glucotrend,
Roche, Rotkreuz, Switzerland) 30 and 0 minutes before,
and 30, 60, 90 and 120 minutes after glucose injection
from a 3.5 µl drop of blood obtained from the tip of the
tail vein.
Analytical methods
Glucose (Trinder kit 100, Sigma, St Louis, MO) and
insulin (ELISA, Mercodia, Uppsala, Sweden) plasma
concentrations were measured in conscious mice (n = 10
for each group), after a 6 hour fast. Total cholesterol,
triglycerides and free fatty acids were measured after an 
8 hour fast in 7 mice of each group by colorimetric enzy-
matic determination (Unimate 5 CHOL and 5 TRIG,
Roche, NEFA-C, Wako). Leptin (Mouse Leptin RIA kit,
Linco, n = 18 for each group) and uric acid (Uric acid plus
kit, SYS 1 BM/Hitachi 917, Roche, n = 7 for each group)
were measured in plasma samples obtained by retro-
orbitary puncture after a 6 hour fast. Fibrinogen was
determined by a clot-rate assay in plasma collected by
cardiac puncture (n = 7 for each group).
Statistical analysis
Data were analysed with the JMP software package
(SAS Institute Inc., Cary, North Carolina, USA). Statisti-
cal analysis was done with ANOVA for between group
comparisons and with the 2-tailed t test for single com-
parisons. All data are presented as mean ± SE. A P value
<0.05 was considered to indicate statistical significance.
Results
As expected, eNOS–/– mice were hypertensive
(mean arterial pressure: 127 ± 6 vs. 99 ± 2 mm Hg,
P = 0.001, Figure 1a) and insulin resistant, as evi-
denced by fasting hyperinsulinaemia (12.0 ± 1.4 vs.
7.1 ± 0.4 mU/ml, P <0.01, Figure 1b) and a roughly
30 percent lower steady state glucose infusion rate
during the hyperinsulinaemic clamp (P <0.001,
Figure 1c). eNOS–/– mice had a 1.5 to 2-fold
elevation of the total cholesterol (1.84 ± 0.03 vs.
1.23 ± 0.06 mmol/l, P <0.01), triglyceride (0.85 ±
0.04 vs. 0.36 ± 0.03 mmol/l, P <0.01) and free fatty
acid (1.9 ± 0.1 vs. 0.9 ± 01 mmol/l, P <0.001) plasma
concentration (Figure 1d). 
Body weight was comparable in both strains
(18.1 ± 0.2 vs. 17.8 ± 0.3 grams, eNOS–/– vs. con-
trol), whereas fat pads (1.9 ± 0.2 vs. 1.3 ± 0.2% of
body weight, eNOS–/– vs. eNOS+/+, P <0.05) and
the leptin plasma concentration were 30 to 40%
higher in the eNOS–/– than in the control mice 
(2.7 ± 0.3 vs. 2.1 ± 0.2 ng/ml, P = 0.02, Figure 2a).
Creatinine plasma concentration was comparable
in eNOS–/– and control mice (33.2 ± 1.3 vs. 35.3 ±
1.6 mmol/litre). Finally, uric acid (69.1 ± 6.7 vs. 47.1
± 7.9 mmol/l, P <0.05, Figure 2b) and fibrinogen
(2.7 ± 0.1 vs. 2.2 ± 0.1 g/l, P <0.005, Figure 2c)
plasma levels were elevated in the eNOS–/– mice.
Since glucose intolerance is often associated
with the metabolic syndrome in humans, we as-
sessed the glycaemic response to an intraperitoneal
glucose administration in control and eNOS–/–
mice fed a normal chow or high fat diet for 6 weeks.
When fed a normal chow, no differences in gly-
caemic excursions were observed during the
glucose tolerance test, whereas on high fat diet
eNOS–/– mice became more glucose intolerant
than control mice (Figure 3). 
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Figure 1
a: mean arterial 
pressure; 
b: fasting insulin
plasma concentra-
tion; 
c: glucose infusion
rate during hyper-
insulinaemic 
euglycaemic clamp
studies; 
d: fasting free fatty
acid, triglyceride 
and total cholesterol
plasma concentra-
tion, in control and
knockout mice. 
Results are mean 
± SEM for at least 
7 mice in each group.
*P <0.05, **P <0.01,
***P <0.001 vs. 
control mice 
Figure 2
a: plasma concen-
tration of leptin; 
b: total fat pads; 
c: fibrinogen; 
d: uric acid in control
and knockout mice. 
Results are mean 
± SEM for at least 
7 mice in each group.
*P <0.05, **P <0.01 
vs. control mice.
Discussion
The main new finding was that a single gene
defect, eNOS deficiency, was associated with a
clustering of cardiovascular risk factors in young
mice. As expected [5], eNOS–/– mice were hyper-
tensive, insulin resistant, and had dyslipidaemia.
Here we show that in addition eNOS–/– mice also
had elevated plasma levels of leptin, uric acid and
fibrinogen and that they developed glucose intol-
erance when challenged with a metabolic stress.
Some components making up the human
metabolic syndrome have already been found to be
associated with defective NO synthesis in mice.
NO plays a major role in the regulation of vascu-
lar tone, and as in the present study, eNOS–/– mice
were found to have systemic arterial hypertension
[5]. In human essential hypertension, endothe-
lium-dependent vasodilatation is impaired [6] and
eNOS gene polymorphism has been reported [7].
Consistent with our previous findings [5] eNOS–/–
mice displayed hyperlipidaemia and insulin re-
sistance, as evidenced by fasting hyperinsulinaemia
and lower steady state glucose infusion rate during
the euglycaemic hyperinsulinaemic clamp studies.
In the human metabolic syndrome, insulin resis-
tance is often associated with impaired glucose
tolerance and eNOS gene polymorphism has been
reported [8]. Here we found that insulin resistance
in eNOS–/– mice when challenged with a meta-
bolic stress (high fat diet), led to altered glucose
homeostasis. Insulin resistance in eNOS–/– mice
could be related to impaired insulin stimulation of
skeletal muscle perfusion (and substrate delivery)
and defects of insulin signalling in the skeletal
muscle cell [5]. In insulin resistant humans similar
mechanisms may play a role, since insulin stimu-
lation of skeletal muscle blood flow, which is 
NO-dependent [9], is defective [4]. 
The augmented leptin plasma levels in
eNOS–/– mice are intriguing. The increase of this
adipocyte-derived signalling factor was not asso-
ciated with increased body weight and was not re-
lated to impaired clearance (as evidenced by the
normal creatinine plasma concentration in the
eNOS–/– mice). However, relative adipose tissue
content was augmented in eNOS–/– mice and 
could have contributed to augmented leptin levels.
Alternatively, it appears possible that the elevated
leptin levels merely reflect the hyperinsulinaemia,
since insulin is known to stimulate leptin produc-
tion [10]. Consistent with this interpretation, it has
been speculated that hyperleptinaemia associated
with the human metabolic syndrome could be
related to insulin [11]. Finally, leptin increases
insulin sensitivity and has depressor actions [12]. It
is tempting to speculate that the elevated leptin
concentration may represent a counter-regulatory
mechanism, opposing the insulin resistance and
hypertension in eNOS–/– mice. In humans, fib-
rinogen is an independent risk factor for coronary
artery disease and is part of the metabolic syn-
drome. The elevation of the fibrinogen plasma
concentration in eNOS–/– mice was of a similar
magnitude to that observed in the human meta-
bolic syndrome. Finally, eNOS–/– mice had ele-
vated uric acid plasma levels, one of the classical
components of the human hypertension-hyper-
glycaemia-hyperuricaemia syndrome first des-
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cribed by Kylin [2] and which has been incrimi-
nated as an independent risk factor for coronary
heart disease, especially in women. 
In conclusion, these findings demonstrate that
a single gene defect, eNOS deficiency, causes an
important clustering of cardiovascular risk factors
in young mice. We speculate that a defect in nitric
oxide synthesis may trigger many of the abnor-
malities making up the metabolic syndrome in
humans, which thereby may represent a new tar-
get for pharmacological agents that deliver and/or
modulate the bioavailability of endogenously pro-
duced nitric oxide [13]. 
We are indebted to Caroline Mathieu, Barbara
Ménard, Marie-Jeanne Voirol and Eric Le Gouill for
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Figure 3
Plasma glucose
concentration during
intraperitoneal
glucose tolerance
tests (IPGTT). Results
are mean ± SEM for 
at least 7 mice in
each group. 
**P <0.01 vs. control
mice.
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